{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:15:22Z","timestamp":1790007322590,"version":"4.0.1"},"reference-count":19,"publisher":"SAGE Publications","issue":"11-12","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies on monthly migraine days after 12 treatment months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-calcitonin gene-related peptide antibodies have been a game changer in migraine prophylaxis. However, high treatment costs warrant reducing treatment duration to the essential minimum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected data of patients with migraine who had received anti-calcitonin gene-related peptide antibodies and had received treatment for 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 52 patients. The average number of monthly migraine days was 16\u2009\u00b1\u20097 days at baseline, 6\u2009\u00b1\u20096 in the third, and 5\u2009\u00b1\u20094 in the 12th treatment month. After treatment interruption, the number of monthly migraine days was 6\u2009\u00b1\u20094 days in the first month, 9\u2009\u00b1\u20094 days in the second, and 11\u2009\u00b1\u20095 days in the third month. Most patients (88.9%) restarted treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only little of the therapeutic effect of anti-calcitonin gene-related peptide antibodies outlasts their pharmacological effect. After treatment interruption, migraine frequency rose in most patients, and prophylaxis was required again in most cases. Limiting treatment to benefitting patients and confirming the need for prophylaxis periodically is reasonable. However, our data does not support the need for prescheduled treatment discontinuation after 12 months and a fixed duration of the treatment interruption of 3 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211014616","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T02:25:05Z","timestamp":1621304705000},"page":"1181-1186","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":53,"title":["Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment \u2013 a real-life cohort study"],"prefix":"10.1177","volume":"41","author":[{"given":"Andreas R","family":"Gantenbein","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurorehabilitation, RehaClinic group, Bad Zurzach, Switzerland"},{"name":"Department of Neurology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Agosti","sequence":"additional","affiliation":[{"name":"Kopfwehzentrum Hirslanden, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocenter of Southern Switzerland (NSI), Ospedale Regionale Lugano Civico, Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Fl\u00fcgel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-6098","authenticated-orcid":false,"given":"Christoph J","family":"Schankin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Inselspital, Berne University Hospital, University of Berne, Berne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Viceic","sequence":"additional","affiliation":[{"name":"Centre M\u00e9dical Montchoisi, Swiss Medical Network, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocenter of Southern Switzerland (NSI), Ospedale Regionale Lugano Civico, Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-6790","authenticated-orcid":false,"given":"Heiko","family":"Pohl","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"bibr1-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779544"},{"key":"bibr2-03331024211014616","unstructured":"Novartis. Annual Report 2019; 2020, https:\/\/www.annualreports.com\/HostedData\/AnnualReportArchive\/n\/NYSE_NVS_2019.pdf (accessed 15 December 2020)."},{"key":"bibr3-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010019"},{"key":"bibr4-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419854082"},{"key":"bibr5-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-1609-7"},{"key":"bibr6-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010600"},{"key":"bibr7-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0985-0"},{"key":"bibr8-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1177\/2514183X18823377"},{"key":"bibr9-03331024211014616","unstructured":"Andr\u00e9e C, Barone-Kaganas I, Biethahn S, et\u00a0al. Therapieempfehlungen f\u00fcr prim\u00e4re Kopfschmerzen. In:\n                      Schweizerische Kopfwehgesellschaft SKG\n                      ; 2019, https:\/\/headache.ch\/download\/Content_attachments\/FileBaseDoc\/SKG_Therapieempfehlungen_DE_19_WEB.pdf"},{"key":"bibr10-03331024211014616","unstructured":"Schweizerisches Heilmittelinstitut Swissmedic. Arzneimittelinformation. In. Bern, http:\/\/www.swissmedicinfo.ch (accessed 15 December 2020)."},{"key":"bibr11-03331024211014616","unstructured":"Bundesamt f\u00fcr Gesundheit. Spezialit\u00e4tenliste. In; 2020, www.spezialit\u00e4tenliste.ch (accessed 15 December 2020)."},{"key":"bibr12-03331024211014616","unstructured":"Human Research Act (HRA). 2013, http:\/\/www.admin.ch\/opc\/en\/classified-compilation\/20121176\/201401010000\/810.305.pdf (accessed 15 December 2020)."},{"key":"bibr13-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1996.1604231.x"},{"key":"bibr14-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1111\/head.12755"},{"key":"bibr15-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"bibr16-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr17-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-05022-z"},{"key":"bibr18-03331024211014616","first-page":"247","volume":"33","author":"de Hoon J","year":"2013","journal-title":"Cephalalgia"},{"key":"bibr19-03331024211014616","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01303.x"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211014616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211014616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211014616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:05Z","timestamp":1777387745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211014616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":19,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/03331024211014616"],"URL":"https:\/\/doi.org\/10.1177\/03331024211014616","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}